2000 liver cancer patients studied to find optimal pre-surgery therapy

NCT ID NCT06405321

First seen Jan 17, 2026 · Last updated May 07, 2026 · Updated 17 times

Summary

This study looks back at the medical records of 2000 people with liver cancer in Guangxi, China, who received treatment before surgery (called conversion or neoadjuvant therapy). The goal is to find out which treatments work best and which patients benefit the most. Researchers will track survival and cancer progression for one year after treatment.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Jian-Hong Zhong

    RECRUITING

    Nanning, China, 530021, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.